Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:BTMD NASDAQ:CMPX NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.62-1.7%$4.95$4.24▼$9.36$322.41M1.56417,033 shs83,367 shsBTMDbiote$2.16-2.5%$1.81$1.27▼$4.75$84.80M1.71222,776 shs106,549 shsCMPXCompass Therapeutics$1.86+1.4%$4.78$1.61▼$6.88$334.07M0.795.45 million shs1.75 million shsSOPHSOPHiA GENETICS$4.71-1.6%$4.86$2.59▼$5.70$321.90M1.01166,115 shs92,199 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-2.29%-2.08%-4.86%-16.52%-43.65%BTMDbiote+1.38%+0.91%+38.99%0.00%-44.61%CMPXCompass Therapeutics0.00%-6.63%-64.60%-72.27%+0.55%SOPHSOPHiA GENETICS-6.99%-9.96%+1.91%+0.21%+63.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.62-1.7%$4.95$4.24▼$9.36$322.41M1.56417,033 shs83,367 shsBTMDbiote$2.16-2.5%$1.81$1.27▼$4.75$84.80M1.71222,776 shs106,549 shsCMPXCompass Therapeutics$1.86+1.4%$4.78$1.61▼$6.88$334.07M0.795.45 million shs1.75 million shsSOPHSOPHiA GENETICS$4.71-1.6%$4.86$2.59▼$5.70$321.90M1.01166,115 shs92,199 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-2.29%-2.08%-4.86%-16.52%-43.65%BTMDbiote+1.38%+0.91%+38.99%0.00%-44.61%CMPXCompass Therapeutics0.00%-6.63%-64.60%-72.27%+0.55%SOPHSOPHiA GENETICS-6.99%-9.96%+1.91%+0.21%+63.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00203.03% UpsideBTMDbiote 2.25Hold$2.7527.61% UpsideCMPXCompass Therapeutics 2.86Moderate Buy$13.60633.15% UpsideSOPHSOPHiA GENETICS 2.33Hold$7.5059.20% UpsideCurrent Analyst Ratings BreakdownLatest BTMD, SOPH, CMPX, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/28/2026CMPXCompass Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/28/2026CMPXCompass Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $7.004/28/2026CMPXCompass Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$10.004/27/2026CMPXCompass Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.004/27/2026CMPXCompass Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026SOPHSOPHiA GENETICS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CMPXCompass Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.004/15/2026SOPHSOPHiA GENETICS BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$72.86M4.42N/AN/A$8.79 per share0.53BTMDbiote$192.22M0.44$0.57 per share3.76($1.40) per share-1.54CMPXCompass Therapeutics$850K393.02N/AN/A$1.11 per share1.67SOPHSOPHiA GENETICS$77.27M4.18N/AN/A$0.69 per share6.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%N/ABTMDbiote$27.05M$0.444.876.34N/A8.29%-24.04%14.46%N/ACMPXCompass Therapeutics-$66.49M-$0.41N/AN/AN/AN/A-39.75%-35.29%5/14/2026 (Estimated)SOPHSOPHiA GENETICS-$79M-$0.52N/AN/AN/A-44.48%-62.74%-21.85%N/ALatest BTMD, SOPH, CMPX, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CMPXCompass Therapeutics-$0.10N/AN/AN/A($0.82) millionN/A5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million5/5/2026Q1 2026CMPXCompass Therapeutics-$0.10-$0.10N/A-$0.10($0.82) millionN/A5/5/2026Q1 2026SOPHSOPHiA GENETICS-$0.2325-$0.27-$0.0375-$0.27$20.40 million$21.69 million4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 million3/18/2026Q4 2025BCYCBicycle Therapeutics-$1.00-$0.29+$0.71-$0.29$7.08 million$47.96 million3/11/2026Q4 2025BTMDbiote$0.05$0.06+$0.01$0.06$45.79 million$46.41 million3/5/2026Q4 2025CMPXCompass Therapeutics-$0.10-$0.09+$0.01-$0.09($0.90) millionN/A3/3/2026Q4 2025SOPHSOPHiA GENETICS-$0.20-$0.28-$0.08-$0.28$21.20 million$21.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66BTMDbioteN/A1.220.79CMPXCompass TherapeuticsN/A19.0419.04SOPHSOPHiA GENETICS1.052.061.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%BTMDbiote21.68%CMPXCompass Therapeutics68.43%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%BTMDbiote32.40%CMPXCompass Therapeutics18.70%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.71 million63.78 millionOptionableBTMDbiote19439.55 million26.74 millionNot OptionableCMPXCompass Therapeutics20180.09 million146.41 millionNot OptionableSOPHSOPHiA GENETICS52068.49 million65.14 millionNot OptionableBTMD, SOPH, CMPX, and BCYC HeadlinesRecent News About These CompaniesAlternate Health (OTCMKTS:AHGIF) and SOPHiA GENETICS (NASDAQ:SOPH) Head-To-Head ReviewMay 12 at 2:13 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), SOPHiA GENETICS (SOPH) and Solventum Corporation (SOLV)May 9 at 8:05 AM | theglobeandmail.comSOPHiA GENETICS (NASDAQ:SOPH) Given Buy Rating at BTIG ResearchMay 7, 2026 | americanbankingnews.comSOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG ResearchMay 6, 2026 | marketbeat.comCritical Comparison: SOPHiA GENETICS (NASDAQ:SOPH) vs. MDxHealth (NASDAQ:MDXH)May 6, 2026 | americanbankingnews.comSOPHiA Genetics (SOPH) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comSOPHiA GENETICS Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comSOPHiA GENETICS SA (SOPH) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPSMay 5, 2026 | marketbeat.comBTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8May 5, 2026 | finance.yahoo.comSOPHiA GENETICS Reports First Quarter 2026 ResultsMay 5, 2026 | prnewswire.comSOPHiA GENETICS (SOPH) to Release Earnings on TuesdayMay 3, 2026 | americanbankingnews.comUncovering MTAP deletions in precision oncology researchApril 30, 2026 | labroots.comLSOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in StockApril 28, 2026 | marketbeat.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Drops By 31.0%April 28, 2026 | marketbeat.comSOPHiA GENETICS (SOPH) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comHow The SOPHiA GENETICS (NasdaqGS:SOPH) Narrative Is Shifting With New Fair Value TargetsApril 26, 2026 | finance.yahoo.comSOPHiA GENETICS SAApril 23, 2026 | edition.cnn.comInsider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 4,486 Shares of StockApril 21, 2026 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026April 21, 2026 | prnewswire.comMount Sinai adopts AI platform to advance genomic testingApril 18, 2026 | beckershospitalreview.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTMD, SOPH, CMPX, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.62 -0.08 (-1.70%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.biote NASDAQ:BTMD$2.15 -0.06 (-2.49%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Compass Therapeutics NASDAQ:CMPX$1.86 +0.03 (+1.37%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.SOPHiA GENETICS NASDAQ:SOPH$4.71 -0.08 (-1.65%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
